分子式:C24H29NO5 ,分子量:411.49076,LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
货号 | 规格 | 数量 | 价格 |
---|---|---|---|
Q-0022450 | 100mg |
1
|
询价 |
Q-0022450 | 250mg |
1
|
询价 |
Q-0022450 | 500mg |
1
|
询价 |
Q-0022450 | 1g |
1
|
询价 |
Q-0022450 | 5g |
1
|
询价 |
参数信息 | |
---|---|
外观状态: | 固体或粉末 |
质量指标: | 95%+ |
溶解条件: | 有机溶剂/水 |
CAS号: | N/A |
分子量: | N/A |
储存条件: | -20℃避光保存 |
储存时间: | 1年 |
运输条件: | 室温2周 |
生产厂家: | 西安齐岳生物科技有限公司 |
-
32487-58-4 3-methoxyfuran-2-carbaldehyde 中间体分子
-
32487-58-4 3-methoxyfuran-2-carbaldehyde 中间体分子
-
分子式: C20H25NO2.HCl ,分子量: 347.87894,LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
-
分子式: C23H29NO4 ,分子量: 383.48066,LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.